Table 1

Effects of PPARs ligands on DSS-induced colitis (experiment 1)

Group no.TreatmentnBody weight(g)Liver weight (g)Relative liver weightaScore of colitis
11%DSS10154 ± 6b8.4 ± 1.15.45 ± 0.583.60 ± 0.66
21% DSS/troglitazone (10 mg/kg bw i.g.)8148 ± 108.5 ± 1.55.73 ± 0.901.88 ± 0.78c
31% DSS/troglitazone (100 mg/kg bw i.g.)8149 ± 98.5 ± 1.25.75 ± 0.981.00 ± 0.87d
41% DSS/bezafibrate (10 mg/kg bw i.g.)8148 ± 118.3 ± 0.85.67 ± 0.671.88 ± 1.05e
51% DSS/bezafibrate (100 mg/kg bw i.g.)8147 ± 39.1 ± 0.86.22 ± 0.541.50 ± 1.00f
6Troglitazone (100 mg/kg bw i.g.)4158 ± 38.2 ± 0.95.23 ± 0.670
7Bezafibrate (100 mg/kg bw i.g.)4153 ± 79.6 ± 1.86.29 ± 0.930
8None4159 ± 58.3 ± 1.15.22 ± 0.590
  • a Liver weight/100 g body weight. bw, body weight; i.g., intragastrically.

  • b Mean ± SD.

  • c Significantly different from group 1: P < 0.005;

  • d P < 0.001;

  • e P < 0.02; and

  • f P < 0.002.